Clinical Study
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes
Table 2
Laboratory data of before and after treatment by alogliptin.
| | | Before | After | value |
| | UAlbCR (mg/g Cr) | 114.6 ± 36.0 | 99.6 ± 26.8 | = 0.198 | | UAGTCR (µg/g Cr) | 27.2 ± 4.2 | 29.9 ± 8.0 | = 0.628 | | HbA1c (NGSP) (%) | 7.2 ± 0.1 | 7.0 ± 0.1 | = 0.00 | | eGFR (mL/min/1.73 m2) | 74.3 ± 3.1 | 72.2 ± 3.0 | = 0.067 | | Systolic blood pressure (mmHg) | 140.5 ± 2.9 | 138.3 ± 2.9 | = 0.130 | | Diastolic blood pressure (mmHg) | 77.8 ± 1.7 | 78.7 ± 1.6 | = 0.763 |
|
|
value < 0.05.
|
